Patent is expected to provide exclusivity until at least 2041.
The United States Patent and Trademark Office has granted U.S. patent No. 11,958,807 for Cybin’s CYB003 program.
The patent, which is expected to provide exclusivity until at least 2041, includes claims to pharmaceutical compositions within the company’s proprietary deuterated psilocybin analog program, CYB003, according to the company.
“As we continue to advance CYB003, our deuterated psilocybin analog program for the adjunctive treatment of [major depressive disorder], further protecting our intellectual property through patent protection is an important achievement,” said Doug Drysdale, CEO of Cybin.
“The strength of our patents supporting CYB003 underscore our commitment to developing innovative, next-generation, commercially scalable therapeutics to address the significant unmet medical need in MDD. With our robust patent portfolio, and the recent breakthrough-therapy designation by the U.S. Food and Drug Administration, we are encouraged by our regulatory pathway for CYB003 and are positioned to move quickly to progress the program.”
Via a news release, Cybin said the company expects to start enrollment for a multinational, multisite Phase 3 program evaluating CYB003 for treating major depressive disorder in the middle of the year.
Cybin’s patent portfolio now includes more than 50 granted patents and more than 170 pending applications, according to the company.